title: Triptans for acute cluster headache.
abstract: BACKGROUND
  Cluster headache is an uncommon, but severely painful and disabling condition, with rapid onset. Validated treatment options are limited, and first-line therapy includes inhaled oxygen. Alternative therapies such as intranasal lignocaine and ergotamine are not as commonly used and are less well studied. Triptans are successfully used to treat migraine attacks and, because of this, they may also be useful for cluster headache.
  
  
  OBJECTIVE
  To determine the efficacy and tolerability of triptans for the acute treatment of cluster headaches.
  
  
  METHODS
  We searched Cochrane CENTRAL, MEDLINE and EMBASE for studies through 22 January 2010.
  
  
  METHODS
  Randomised, double-blind, placebo-controlled studies of triptans for acute treatment of cluster headache episodes.
  
  
  METHODS
  Two review authors independently assessed study quality and extracted data. Numbers of participants with different levels of pain relief, requiring rescue medication and experiencing adverse events and headache-associated symptoms in treatment and control groups were used to calculate relative risk and numbers needed to treat (NNT) and harm (NNH).
  
  
  RESULTS
  All six included studies used a single dose of triptan to treat an attack of moderate to severe pain intensity. In total 231 participants received zolmitriptan 5 mg, 223 received zolmitriptan 10 mg, 131 received sumatriptan 6 mg, 88 received sumatriptan 12 mg, and 326 received placebo. Zolmitriptan was administered either orally or intranasally, and sumatriptan either subcutaneously or intranasally.Overall, the triptans studied were better than placebo for headache relief and pain-free responses, with an NNT of 2.4 for 15 minute pain relief with subcutaneous sumatriptan 6 mg (75% with sumatriptan and 32% with placebo), and 2.8 for 30 minute pain relief with intranasal zolmitriptan 10 mg (62% with zolmitriptan and 26% with placebo). Fewer participants need rescue medication with triptan than with placebo, but more experienced adverse events.
  
  
  CONCLUSIONS
  Zolmitriptan and sumatriptan are effective in the acute treatment of cluster headaches and may provide a useful treatment option, potentially offering convenience over oxygen therapy and a better safety and tolerability profile than ergotamine. Non-oral routes of administration are likely to provide better and more rapid responses.
authors.affiliation: Pain Research and Nuffield Department of Anaesthetics, University of Oxford, West Wing (Level 6), John Radcliffe Hospital, Oxford, Oxfordshire, UK, OX3 9DU.
authors.forename: Simon
authors.initials: S
authors.lastname: Law
authors.forename: Sheena
authors.initials: S
authors.lastname: Derry
authors.forename: R Andrew
authors.initials: RA
authors.lastname: Moore
mesh_terms: D003027:Cluster Headache / Q000188:drug therapy*; D006801:Humans; D023303:Oxazolidinones / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use*; D018170:Sumatriptan / Q000627:therapeutic use; D014363:Tryptamines / Q000627:therapeutic use*
chemical_list: D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan; D018170:Sumatriptan
references.citation: Neurology. 2007 Aug 28;69(9):821-6
references.pmid: 17724283
references.citation: Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005219
references.pmid: 18646121
references.citation: Neurology. 2000 May 9;54(9):1832-9
references.pmid: 10802793
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Neurology. 2003 Feb 25;60(4):630-3
references.pmid: 12601104
references.citation: Headache. 1978 Mar;18(1):9-19
references.pmid: 649381
references.citation: BMJ. 1995 Feb 18;310(6977):452-4
references.pmid: 7873954
references.citation: Eur Neurol. 1994;34 Suppl 2:35-9
references.pmid: 7835381
references.citation: Cephalalgia. 1995 Dec;15(6):452-62
references.pmid: 8706107
references.citation: Cephalalgia. 1998 Sep;18(7):487-9
references.pmid: 9793702
references.citation: Lancet. 1998 Jul 25;352(9124):275-8
references.pmid: 9690407
references.citation: Acta Neurol Scand. 1993 Jul;88(1):63-9
references.pmid: 8396833
references.citation: Cephalalgia. 2000 Oct;20(8):687-95
references.pmid: 11167896
references.citation: Br Med J (Clin Res Ed). 1988 May 7;296(6632):1313-6
references.pmid: 3133061
references.citation: Expert Opin Drug Saf. 2003 Mar;2(2):123-32
references.pmid: 12904112
references.citation: Ann Intern Med. 1987 Aug;107(2):224-33
references.pmid: 3300460
references.citation: Cephalalgia. 1986 Sep;6(3):159-62
references.pmid: 3768949
references.citation: Headache. 2004 May;44 Suppl 1:S20-30
references.pmid: 15149490
references.citation: Am J Med. 2001 Nov;111(7):553-8
references.pmid: 11705432
references.citation: Drugs. 1994 Apr;47(4):622-51
references.pmid: 7516861
references.citation: N Engl J Med. 1991 Aug 1;325(5):322-6
references.pmid: 1647496
references.citation: Cephalalgia. 1988;8 Suppl 7:1-96
references.pmid: 3048700
references.citation: Curr Pain Headache Rep. 2009 Apr;13(2):168-78
references.pmid: 19272285
references.citation: Arch Neurol. 2006 Nov;63(11):1537-42
references.pmid: 16966497
references.citation: Cephalalgia. 2004;24 Suppl 1:9-160
references.pmid: 14979299
references.citation: Neurology. 1998 Sep;51(3):908-11
references.pmid: 9748059
references.citation: Pain. 1998 Dec;78(3):209-216
references.pmid: 9870574
references.citation: Neurology. 2005 Feb 8;64(3):469-74
references.pmid: 15699377
references.citation: Headache. 2009 Oct;49(9):1315-23
references.pmid: 19788472